HK1046636A1 - 多晶型托拉塞米 - Google Patents

多晶型托拉塞米 Download PDF

Info

Publication number
HK1046636A1
HK1046636A1 HK02108111.5A HK02108111A HK1046636A1 HK 1046636 A1 HK1046636 A1 HK 1046636A1 HK 02108111 A HK02108111 A HK 02108111A HK 1046636 A1 HK1046636 A1 HK 1046636A1
Authority
HK
Hong Kong
Prior art keywords
torsemide
adduct
polymorphs
disclosed
methods
Prior art date
Application number
HK02108111.5A
Other languages
English (en)
Chinese (zh)
Inventor
Aronhime Judith
Leonov David
Kordova Marko
Schwartz Anchel
Dolitzky Ben-Zion
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1046636A1 publication Critical patent/HK1046636A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
HK02108111.5A 1999-08-11 2000-08-11 多晶型托拉塞米 HK1046636A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US60/148,305 1999-08-11
US18312700P 2000-02-17 2000-02-17
US60/183,127 2000-02-17
US21527300P 2000-06-30 2000-06-30
US60/215,273 2000-06-30
PCT/US2000/022081 WO2001010441A1 (en) 1999-08-11 2000-08-11 Torsemide polymorphs

Publications (1)

Publication Number Publication Date
HK1046636A1 true HK1046636A1 (zh) 2003-01-24

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108111.5A HK1046636A1 (zh) 1999-08-11 2000-08-11 多晶型托拉塞米

Country Status (24)

Country Link
US (1) US6465496B1 (https=)
EP (1) EP1207880A4 (https=)
JP (1) JP2003527319A (https=)
KR (1) KR20020025217A (https=)
CN (1) CN1378448A (https=)
AU (1) AU781461C (https=)
BG (1) BG106400A (https=)
CA (1) CA2379322A1 (https=)
CZ (1) CZ2002404A3 (https=)
DE (1) DE00957398T1 (https=)
ES (1) ES2204354T1 (https=)
HK (1) HK1046636A1 (https=)
HR (1) HRP20020120A2 (https=)
HU (1) HUP0204318A3 (https=)
IL (1) IL148031A0 (https=)
LT (1) LT5004B (https=)
MX (1) MXPA02001369A (https=)
NO (1) NO20020622L (https=)
PL (1) PL354262A1 (https=)
SI (1) SI20816A (https=)
SK (1) SK1912002A3 (https=)
TR (1) TR200200353T2 (https=)
WO (1) WO2001010441A1 (https=)
YU (1) YU9502A (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200401462T4 (tr) * 2000-02-17 2004-08-23 Teva Pharmaceutical Industries Ltd. Torsemid modifikasyonu II' yi içeren dengeli bir farmasötik formülasyonu
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
CA2448279A1 (en) 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
IN192178B (https=) 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30633A (en) 1860-11-13 Improvement in fire-escapes
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
HRP20020819A2 (en) * 2000-03-20 2004-12-31 Teva Pharma Novel processes for preparing torsemide intermediate
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Also Published As

Publication number Publication date
ES2204354T1 (es) 2004-05-01
PL354262A1 (en) 2003-12-29
CA2379322A1 (en) 2001-02-15
AU6902600A (en) 2001-03-05
JP2003527319A (ja) 2003-09-16
SK1912002A3 (en) 2002-07-02
EP1207880A1 (en) 2002-05-29
AU781461C (en) 2006-02-23
EP1207880A4 (en) 2004-09-01
TR200200353T2 (tr) 2002-06-21
LT2002017A (en) 2002-11-25
CZ2002404A3 (cs) 2002-06-12
CN1378448A (zh) 2002-11-06
AU781461B2 (en) 2005-05-26
WO2001010441A1 (en) 2001-02-15
LT5004B (lt) 2003-03-25
NO20020622L (no) 2002-03-14
HUP0204318A2 (en) 2003-05-28
NO20020622D0 (no) 2002-02-08
IL148031A0 (en) 2002-09-12
HUP0204318A3 (en) 2005-03-29
BG106400A (en) 2002-08-30
HRP20020120A2 (en) 2003-10-31
YU9502A (sh) 2005-06-10
DE00957398T1 (de) 2004-04-15
KR20020025217A (ko) 2002-04-03
SI20816A (sl) 2002-08-31
US6465496B1 (en) 2002-10-15
MXPA02001369A (es) 2005-08-26

Similar Documents

Publication Publication Date Title
HK1046636A1 (zh) 多晶型托拉塞米
CA2214793A1 (en) Novel intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds
CA2419314A1 (en) Preparation of risperidone
AU5681800A (en) Quinoline derivatives as antibacterials
AU3631197A (en) N-benzylpiperidine and tetrahydropyridine derivatives
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
HUP9601033A2 (en) Benzofurane derivatives, process for their preparation, use of them as intermediate and pharmaceutical compositions containing the compounds
HUP9700126A3 (en) 2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazotidinone derivatives and pharmaceutical compositions containing them, process for producing the compounds and intermediates of them
WO2001010816A3 (de) Substituierte 2-Dialkylaminoalkylbiphenyl-derivate
IL139861A0 (en) 17β-AMINO-AND HYDROXYLAMINO -11 β-ARYLSTEROID DERIVATIVES, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CA2412047A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
HK1046902A1 (zh) 新型哌嗪基烷基硫代嘧啶衍生物，包含該衍生物的藥物組合物以及製備該活性物質的方法
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
AU6551198A (en) Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
WO1999058490A3 (en) Novel aryl-hydro naphthalenal kanamines
HK1055058A2 (en) 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
WO2001062765A3 (en) Small molecule modulators of g protein-coupled receptor six
WO2001002340A3 (en) Novel aminoindanes
HK1050002A1 (zh) 嶄新的吡唑[4，3-e]二氮雜草代替品、含有上述物質的藥用合成物、作藥用產品的用途及其製造過程
CA2258539A1 (en) Ring-fused dihydropyranes, process for the preparation and use thereof
WO1999058527A3 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
HK1055059A2 (en) 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
WO2001083423A3 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents